Presentation is loading. Please wait.

Presentation is loading. Please wait.

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy  Apar Pataer, MD, PhD, Neda Kalhor,

Published by Modified over 5 years ago

Similar presentations

Presentation on theme: "Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy  Apar Pataer, MD, PhD, Neda Kalhor,"— Presentation transcript:

1 Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy  Apar Pataer, MD, PhD, Neda Kalhor, MD, Arlene M. Correa, PhD, Maria Gabriela Raso, MD, Jeremy J. Erasmus, MD, Edward S. Kim, MD, Carmen Behrens, MD, J. Jack Lee, PhD, Jack A. Roth, MD, David J. Stewart, MD, Ara A. Vaporciyan, MD, Ignacio I. Wistuba, MD, Stephen G. Swisher, MD  Journal of Thoracic Oncology  Volume 7, Issue 5, Pages (May 2012) DOI: /JTO.0b013e a Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Schematic diagram of histologic evaluation of lung cancer tissue resected from patients treated with neoadjuvant chemotherapy. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e a) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Pathologic response to neoadjuvant chemotherapy for lung cancer. Representative examples of the histopathology of tumors associated with extensive response to treatment (A, C) or no response to treatment (B, D). Arrows indicate viable tumor cells (C, D). Original magnification: ×40 (pictures) and ×200 (insets). Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e a) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Kaplan-Meier estimates of overall survival (A, C) and disease-free survival (B, D) based on pathologic stages (A, B) and percentage of viable tumor cells (C, D). A, The overall survival was significantly longer in patients with stages 0, IA, and IB than in patients with pathologic stage II, III, or IV. B, The disease-free survival was significantly longer in patients with stages 0, IA, and IB than in patients with pathologic stage II, III, or IV. C, The overall survival was significantly longer in patients with ⩽10% viable tumor cells than in patients with >10% viable tumor cells. D, The disease-free survival was significantly longer in patients with ⩽10% viable tumor cells than in patients with >10% viable tumor cells. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e a) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy  Apar Pataer, MD, PhD, Neda Kalhor,"

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 
The evolution of treatment outcomes for resected stage IIIA non–small cell lung cancer over 16 years at a single institution  Linda W. Martin, MD, Arlene.

The evolution of treatment outcomes for resected stage IIIA non–small cell lung cancer over 16 years at a single institution  Linda W. Martin, MD, Arlene.
Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up  Marco Lucchi, MD, Franca Melfi, MD, Paolo.

Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up  Marco Lucchi, MD, Franca Melfi, MD, Paolo.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer  Stephen G. Swisher, MD, Mary Maish, MD, Jeremy J. Erasmus, MD, Arlene.

Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer  Stephen G. Swisher, MD, Mary Maish, MD, Jeremy J. Erasmus, MD, Arlene.
Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis

Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Puja Gaur, MD, Wayne L. Hofstetter, MD, B

Puja Gaur, MD, Wayne L. Hofstetter, MD, B
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population  Edmund S. Kassis, MD, Ara A. Vaporciyan,

Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population  Edmund S. Kassis, MD, Ara A. Vaporciyan,
Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Tina Cascone, MD, PhD, Kathryn A. Gold, MD, Stephen G

Tina Cascone, MD, PhD, Kathryn A. Gold, MD, Stephen G

Similar presentations

Ads by Google